| Application no. and date | 11715691.9 (espacenet) (Federated) (European Patent Register), 20110414 | | Patent/reg. no. and date | DK/EP 2558095, 20181024 | | Publication date | 20130220 | | Priority no. and date | US 324936 P, 20100416 | | EP pub. no. and date |
EP 2558095 20130220 | | Effective date | | | Applicant/owner | Novartis AG, Lichtstrasse 35
4056 Basel, CH | | Applicant ref. no. | T5863_DK | | Inventor | SHI, Michael, Novartis Pharmaceuticals Corporation
One Health Plaza
East Hanover, NJ 07936, US,
GRAUS-PORTA, Diana, Novartis Pharma AG
Postfach
4002 Basel, CH,
SCHMID, Herbert, Novartis Pharma AG
Postfach
4002 Basel, CH | | Representative | Orsnes Patent ApS, Sentvedvej 23, 5853 Ørbæk, DK | | Opponent | | | IPC Class | A61K 31/496 (2006.01) , A61P 35/00 (2006.01) | | Title | ORGANISK FORBINDELSE TIL ANVENDELSE I BEHANDLING AF LEVERCANCER | | Int. application no. | EP2011055906 | | Int. publication no. | WO2011128403 | | Related patent (certificate) | | | Status | DK/EP patent | | Pædiatrisk forlængelse | - | | Udløbsdato for pædiatrisk forlængelse | - |
|
